Pancreatic Cancer Research

ResearcherWenzhou Medical UniversityNo recent work listed

Yangyang Guo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0002-0238-6958; OpenAlex author ID A5045485102. Sources: OpenAlex.

Their work

Papers
13
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2019: 1 paper · 2020: 4 papers · 2021: 5 papers · 2022: 2 papers · 2023: 1 paper

Papers 13

  1. STAT3 inhibition enhances gemcitabine sensitivity in pancreatic cancer by suppressing EMT, immune escape and inducing oxidative stress damage. Co-author DOI 10.1016/j.intimp.2023.110709↗
  2. The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress p… Co-author DOI 10.1038/s41419-022-04573-7↗
  3. Correction: The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability an… Co-author DOI 10.1038/s41419-022-04705-z↗
  4. Quercetin suppresses pancreatic ductal adenocarcinoma progression via inhibition of SHH and TGF-β/Smad signaling pathways. Co-author DOI 10.1007/s10565-020-09562-0↗
  5. Correction to: Chemopreventive effect of Betulinic acid via mTOR -Caspases/Bcl2/Bax apoptotic signaling in pancreatic cancer. Co-author DOI 10.1186/s12906-021-03254-w↗
  6. NUDCD1 knockdown inhibits the proliferation, migration, and invasion of pancreatic cancer via the EMT process. Co-author DOI 10.18632/aging.203276↗
  7. The anti-dysenteric drug fraxetin enhances anti-tumor efficacy of gemcitabine and suppresses pancreatic cancer development by antagonizing STAT3 activation. Co-author DOI 10.18632/aging.203301↗
  8. The isoflavone puerarin exerts anti-tumor activity in pancreatic ductal adenocarcinoma by suppressing mTOR-mediated glucose metabolism. Co-author DOI 10.18632/aging.203725↗
  9. Chemopreventive effect of Betulinic acid via mTOR -Caspases/Bcl2/Bax apoptotic signaling in pancreatic cancer. Co-author DOI 10.1186/s12906-020-02976-7↗
  10. The Anti-Dysenteric Drug Fraxetin Enhances Anti-Tumor Efficacy of Gemcitabine and Suppresses Pancreatic Cancer Development by Antagonizing STAT3 Activation Co-author DOI 10.21203/rs.3.rs-125318/v1↗
  11. CC-223, NSC781406, and BGT226 Exerts a Cytotoxic Effect Against Pancreatic Cancer Cells via mTOR Signaling. Co-author DOI 10.3389/fphar.2020.580407↗
  12. Molecular Mechanism of Pancreatic Stellate Cells Activation in Chronic Pancreatitis and Pancreatic Cancer. Co-author DOI 10.7150/jca.38616↗
  13. The DNA methylation profile of non-coding RNAs improves prognosis prediction for pancreatic adenocarcinoma. Co-author DOI 10.1186/s12935-019-0828-8↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hengyue Zhu · 10 shared papers, 2020–2022 · strength 1.38
  2. Yongheng Bai · 8 shared papers, 2020–2023 · strength 1.11
  3. Hangcheng Guo · 7 shared papers, 2020–2023 · strength 0.97
  4. Yanyi Xiao · 6 shared papers, 2020–2022 · strength 0.79
  5. Qiyu Zhang · 4 shared papers, 2020–2022 · strength 0.53
  6. Linxiao Sun · 3 shared papers, 2020–2021 · strength 0.45
  7. Cheng Wang · 3 shared papers, 2020–2021 · strength 0.45
  8. Miaomiao Lin · 2 shared papers, 2022 · strength 0.30
  9. Bicheng Chen · 2 shared papers, 2019–2020 · strength 0.24
  10. Junjie Deng · 2 shared papers, 2020–2021 · strength 0.23
  11. Jiawei Chen · 1 shared paper, 2023 · strength 0.18
  12. Guihua Jin · 1 shared paper, 2020 · strength 0.15
  13. Zhensheng Cao · 1 shared paper, 2021 · strength 0.14
  14. Chunling Shi · 1 shared paper, 2021 · strength 0.14
  15. Hewei Zhang · 1 shared paper, 2020 · strength 0.13
  16. Xiangyang Lin · 1 shared paper, 2021 · strength 0.13
  17. Yunfeng Shan · 1 shared paper, 2021 · strength 0.13
  18. Jie Zhang · 1 shared paper, 2019 · strength 0.09
  19. Wanqing Weng · 1 shared paper, 2019 · strength 0.09
  20. Weiguo Huang · 1 shared paper, 2019 · strength 0.09
  21. Keqing Shi · 1 shared paper, 2019 · strength 0.09
  22. Yukai Xiang · 1 shared paper, 2019 · strength 0.09
  23. Mengtao Zhou · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.